Frontlight ResearchEarly access
Not yet recruitingPhase 2
Retinoic acid and sperm production in infertile men
Key facts
- Who runs it
- Les Hopitaux Universitaires De Strasbourg
- Where
- France3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional
- Record updated
- 9 April 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (31)Hide the full registry criteria
Who can take part
- Male aged between 21 and 55 years (inclusive)
- Diagnosed with oligozoospermia [fewer than 15 million spermatozoa per ml, fewer than 39 million per ejaculate], confirmed by two separate semen analyses performed at least one month apart and conducted prior to the inclusion visit (within the 12 months preceding inclusion), as part of routine care
- Infertility lasting more than 12 months
- Patient affiliated with or benefiting from a health insurance scheme
- Patient able to understand the objectives and risks of the study and provide dated and signed informed consent
- Patient informed of the results of the preliminary medical examination
Who cannot take part
- Current treatment with vitamin A
- Surgery of the genitourinary tract in the year preceding inclusion
- Prior treatment with isotretinoin (e.g., Acnetrait, Contracné, Curacné, Procuta) within the 3 months prior to the inclusion visit
- Use of systemic medication within the 3 months prior to inclusion
- Patient currently in an exclusion period (as determined by a previous or ongoing study)
- Ongoing treatment with other retinoids (e.g., acitretin, alitretinoin)
- Known hepatic insufficiency, defined by ASAT/ALAT >2x upper limit of normal at the inclusion visit
- History of severe allergic or anaphylactic reactions
- Known psychiatric disorder (e.g., depression, psychotic symptoms, mood changes), defined by an MDI score >15 at inclusion
- Known history of suicide attempts or known suicide risk
- Any other clinically significant comorbid condition interfering with spermatogenesis
- Hypersensitivity to isotretinoin or any of its excipients
- Known severe renal insufficiency, defined by albuminuria and/or abnormal blood creatinine levels at the inclusion visit
- Known hyperlipidemia defined by elevated triglycerides >1 g/L
- Known allergy to peanut oil, soybean oil, or magnesium stearate
- Known genetic cause of infertility (e.g., chromosomal abnormalities)
- Tobacco use (more than 5 cigarettes per day)
- Chronic alcohol consumption
- Patient with hypogonadotropic hypogonadism
- Patient informed of and consenting not to donate blood during treatment and for 1 month after its completion
- Patient under legal guardianship or curatorship
- Patient under judicial protection
- Inability to provide informed consent (e.g., emergency situations, comprehension difficulties, language barriers, etc.)
- Known hypervitaminosis A defined by levels >800 µg
- Ongoing treatment interfering with spermatogenesis and/or vitamin A metabolism (e.g., tetracyclines, rifampicin, phenytoin, phenobarbital, antiretrovirals, or other CYP enzyme inducers)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Oligozoospermia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate, in terms of sperm production, the effectiveness of treatment with isotretinoin in patients with oligozoospermia.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
Download the PDF
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2024-519644-33-00, who can take part
- Record updated
- 9 April 2026